Abingworth
Life sciences investor funding biotech companies developing new therapeutics
- Venture capital
- London
- Type
- Venture capital
- Based in
- London
- Stages
- Pre-seed, Seed, Series A, Series B+, Growth
- Sector focus
- Sector-agnostic
- Cheque size
- Above €3M
- Fund size
- Undisclosed
- Founded
- 1987
- Website
- abingworth.com
A life sciences investment firm founded in 1987 and headquartered in London, with further offices in New York and San Francisco. It backs entrepreneurs turning scientific discoveries into new medicines, concentrating on biotech and biopharma companies.
Early-stage venture investment is central to its approach, and it also uses venture investments in public equities (VIPEs) and clinical co-development deals, where it funds late-stage trials of drug candidates. The firm says it has invested in more than 100 biotech companies since it was established.
← All investors · Is this your organisation? Request an update
More investors in the directory
The Craftory
Purpose-driven consumer packaged goods brands with category-changing potential
Symvan Capital
EIS and SEIS funds backing B2B SaaS and technology companies from seed to exit
Grafton Capital
Growth capital for European software, AI and tech-enabled businesses
Blackfinch Ventures
EIS and VCT investment in early and growth-stage UK technology businesses
The Conduit Connect
Impact-led UK startups from pre-seed to Series A in climate, health and financial resilience
TrueSight Ventures
Angel-sized cheques at pre-seed and seed, sector-agnostic, into technology companies
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.